Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €1.22 EUR
Change Today 0.00 / 0.00%
Volume 0.0
VSC On Other Exchanges
Symbol
Exchange
Xetra
OTC US
Xetra
As of 3:35 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

4sc ag (VSC) Snapshot

Open
€1.34
Previous Close
€1.22
Day High
€1.34
Day Low
€1.21
52 Week High
04/8/15 - €7.75
52 Week Low
03/10/15 - €3.00
Market Cap
62.2M
Average Volume 10 Days
58.8K
EPS TTM
€-0.19
Shares Outstanding
50.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for 4SC AG (VSC)

Related News

No related news articles were found.

4sc ag (VSC) Related Businessweek News

No Related Businessweek News Found

4sc ag (VSC) Details

4SC AG researches and develops small-molecule drugs for the treatment of cancer and autoimmune diseases. The company operates through two segments, Development and Discovery & Collaborative Business. Its product portfolio in the area of autoimmune includes Vidofludimus, an orally administered small-molecule drug, which is in Phase II b clinical trial for the treatment of crohn’s diseases. The company’s product portfolio in the area of oncology comprises Resminostat, an oral pan-histone-deacetylase inhibitor, which is in Phase II and Phase I clinical trials for the treatment of liver cancer, hodgkin lymphoma, colorectal cancer, non-small-cell lung cancer, and solid tumors; 4SC-202, an epigenetic anti-cancer compound that is in Phase I clinical trials for the treatment of hematologic tumors; and 4SC-205, an anti-cancer compound, which is in Phase I clinical trials for the treatment of solid tumors. It also conducts research programs in the areas of cancer immunotherapy, cancer stem cells, epigenetics, cytokine modulation, and ion channel blockers for the treatment of autoimmune, inflammatory eye, and oncology diseases. The company was founded in 1997 and is headquartered in Martinsried, Germany.

47 Employees
Last Reported Date: 03/25/15
Founded in 1997

4sc ag (VSC) Top Compensated Officers

Chairman of Management Board, Chief Executive...
Total Annual Compensation: €278.0K
Co-Founder, Chief Scientific Officer, Chief D...
Total Annual Compensation: €198.0K
Compensation as of Fiscal Year 2013.

4sc ag (VSC) Key Developments

4SC AG Signs Licensing and Development Agreement with Menarini AP

4SC AG and Menarini Asia-Pacific Holdings Pte. Ltd. announced that they have entered into a licensing and development partnership for 4SC's cancer compound resminostat for the Asia-Pacific region excluding Japan (APAC). Menarini AP will receive the exclusive licensing rights for the development and marketing of resminostat in all APAC countries, including among others China, South Korea, Australia, Thailand, Philippines, Indonesia, and Vietnam. Menarini AP will be responsible for the clinical development, regulatory approval and commercialization of resminostat in China, and other territories included in the agreement, in all oncological indications, and in particular liver cancer (HCC). 4SC will receive upfrontpayments totaling approximately up to EUR 95 million from Menarini payable upon achieving specified development, regulatory and commercialization milestones. In addition, 4SC will be eligible to double-digit royalties linked to product sales of resminostat.

Susanne Danhauser-Riedl Joins 4SC as Chief Medical Officer

4SC AG announced the appointment of Dr. Susanne Danhauser-Riedl as the company's Chief Medical Officer (CMO). Dr. Danhauser-Riedl will take over management of clinical development at 4SC AG from 1 April 2015 and thus assume responsibility for the further clinical development of the company's oncology pipeline, including the compounds resminostat, 4SC-202 and 4SC-205. As Chief Medical Officer, she will report directly to Management Board Member and Chief Development Officer (CDO) & Chief Scientific Officer (CSO) Dr. Daniel Vitt. Dr. Susanne Danhauser-Riedl is a medical doctor and has long standing experience in the fields of haematology and oncology. She has over 20 years of management experience both in research and clinical practice and in the fields of Medical Affairs and clinical development in the pharmaceutical industry. Prior to joining 4SC, she spent almost ten years at the pharmaceutical company GlaxoSmithKline GmbH & Co. KG (GSK).

4SC AG Announces Earnings Results for the Year Ended December 31, 2014

4SC AG announced earnings results for the year 2014. Revenue increased by 44% year on year to EUR 7.06 million compared to EUR 4.90 million a year ago. This positive revenue performance was driven by stable business with research collaborations at Group subsidiary 4SC Discovery GmbH and the delivery of the resminostat compound to the partner Yakult Honsha for clinical trials in Japan. LBIT was EUR 9.44 million compared to EUR 10.59 million a year ago. The loss for the period decreased by 8% to EUR 9.70 million compared to EUR 10.53 million a year ago. Loss per share improved by 10% to EUR 0.19 compared to EUR 0.21 a year ago, because in addition to the improved consolidated net loss there was also a higher average number of shares in financial year 2014 due to the conversion of convertible notes issued in March and September. This results in an average monthly outflow of cash from operations amounting to EUR 0.71 million compared to EUR 0.60 million per month.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VSC:GR €1.22 EUR 0.00

VSC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VSC.
View Industry Companies
 

Industry Analysis

VSC

Industry Average

Valuation VSC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.4x
Price/Book 29.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact 4SC AG, please visit www.4sc.de. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.